C5751003 An Open-Label, Randomized, Controlled Phase 3 Study Of Sigvotatug Vedotin In Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy As First-Line Treatment In Participants With Pd-L1 High (≥50% Of Tumor Cells Expressing Pd-L1), Locally Advanced, Unresectable, Or Metastatic Non-Small Cell Lung Cancer (Be6a Lung-02)
- Phase III
- Trial Category: Lung
Contact(s)
Mary Beth Wilwerding, RN Admin@NEcancertrials.com
Location(s)
Available at Nebraska Cancer Specialists, Omaha and Grand Island, NE locations and available at Cancer Partners of Nebraska, Lincoln, NE
Interested in More Information?
Please fill out the form below. Someone will get back to you as soon as possible.
"*" indicates required fields